Annexon biosciences reports phase 2 clinical trial results demonstrating upstream classical complement inhibition associated with clinical benefit in huntington's disease

Anx005 demonstrated full c1q target inhibition and was generally well-tolerated
ANNX Ratings Summary
ANNX Quant Ranking